Background
==========

Genome-wide association studies (GWAS) have identified many novel susceptibility genes for type 2 diabetes (T2D) since 2007. In the early GWAS, common variants in *IGF2BP2*, *CDKAL1*, *SLC30A8*, *HHEX*, *CDKN2A/B*, *FTO*, and *TCF2*loci were reported to increase the risk of T2D in Caucasians \[[@B1]-[@B6]\], and *KCNQ1*was recently discovered as a new diabetogenic gene in Japanese samples \[[@B7]\]. In addition, the Wolfram syndrome 1(*WFS1*) gene is one of the novel susceptibility genes for T2D identified by the candidate gene approach in Caucasians until recently \[[@B8]\]. Compared with the susceptibility genes for T2D revealed in the following meta-analysis of GWAS \[[@B9]\], these 9 genes, which were discovered in relatively smaller samples, might represent the most diabetogenic genes and have larger effect sizes in the studied populations. Although these associations have been replicated in Caucasians, the roles of some loci remain less clear in Chinese. For example, in the Chinese Han population, the associations between single nucleotide polymorphisms (SNPs) at the *HHEX, IGF2BP2, TCF2, and FTO*loci with T2D were not consistently replicated \[[@B6],[@B10]-[@B15]\], and the findings in previous studies involving Caucasians for SNPs at the *WFS1*locus have not been confirmed \[[@B12]\]. Moreover, in contrast to the large-scale association studies in a European Caucasian population, such studies in China often have a relatively small sample size, and meta-analysis is becoming particularly useful to evaluate the effects of these genes.

Therefore, we hypothesized that the aforementioned genes were also the most important susceptibility genes for T2D in the Chinese Han population living in China. We aimed to test this hypothesis in a case-control study and perform a meta-analysis of all published data for these genetic loci in the Chinese Han population to fully evaluate their effects.

Methods
=======

Subjects
--------

A total of 2029 individuals, including 1024 patients with T2D and 1005 control subjects, were included in the present study. All participants were unrelated and of Northern Han Chinese ancestry residing in the Beijing metropolitan area. The patients were recruited from the Endocrinology and Metabolism Outpatient Clinics of Peking University People\'s Hospital in Beijing, China, and were diagnosed with T2D in accordance with the 1999 WHO criteria (fasting plasma glucose ≥7.0 mmol/l and/or 2-h plasma glucose ≥11.1 mmol/l) \[[@B16]\]. Patients diagnosed with T2D before 30 years of age, those with an elevated body mass index (BMI; \> 35 kg/m^2^), or those with other clinical and genetic features for specific-type diabetes (e.g., maturity onset diabetes of the young \[MODY\]) were excluded from the study \[[@B17],[@B18]\]. The control subjects were selected from communities near Peking University People\'s Hospital. The inclusion criteria for the control subjects in this study were as follows: (1) normal glucose regulation confirmed by a 75 g oral glucose tolerance test (OGTT) according to the 1999 WHO criteria (fasting plasma glucose \<6.1 mmol/l and 2-h plasma glucose \<7.8 mmol/l), (2) no family history of T2D, (3) \>40 years of age, and (4) a BMI ≤ 35 kg/m^2^. The clinical features of the participants are summarized in Table [1](#T1){ref-type="table"}. Informed consent was obtained from every participant, and the study protocol was approved by the Ethics Committee of Peking University People\'s Hospital.

###### 

Clinical characteristics of the participants.

  Characteristics             Controls              Patients     *P*
  --------------------------- --------------------- ------------ -----------
  Male/Female                 343/662               540/484      \<0.00001
  Age at examination(years)   58 ± 9                56 ± 12      \<0.00001
  BMI(kg/m^2^)                25.0 ± 3.3            25.0 ± 3.1   0.87
  Age of diagnosis(years)     \--                   49 ± 11      \--
  Fasting glucose (mmol/l)    5.2 ± 0.4             7.8 ± 2.8    \<0.00001
  Glucose at 2 h (mmol/l)     5.7 ± 1.2             \--          \--
  Fasting insulin (pmol/l)    53.1(38.0-77.5)       \--          \--
  HOMA-IR                     1.60(1.13-2.36)       \--          \--
  HOMA-ß                      80.51(57.63-111.72)   \--          \--

Data are the mean ± SD or median(interquartile range). *p*represents the significance of the differences between the patients and controls.

The gender distribution between the patients and controls was analyzed using Pearson\'s χ^2^test.

Comparison of the quantitative variables between patients and controls was performed using Student\'s t-test.

Anthropometric and biological measurements
------------------------------------------

All of the patients with T2D and control subjects were examined in the morning after an overnight fast for at least 8 hours, with measurements of height, weight, and blood pressure. Blood samples were collected for biochemical measurements of fasting plasma glucose for all the participants, and 2-hour plasma glucose during a 75 g OGTT for the controls. The plasma glucose concentrations were measured by the glucose oxidase-peroxidase method. The fasting serum insulin concentrations were measured by an electrochemiluminescence immunoassay on a Roche Elecsys 2010 Chemistry Analyzer. The homeostasis model assessment of the insulin resistance index (HOMA-IR) and beta-cell function (HOMA-ί) were assessed, as described previously \[[@B19]\].

Genotyping
----------

Nine SNPs representing nine genes identified in recent GWAS or large candidate gene studies \[[@B1]-[@B8]\] were selected, including *SLC30A8-*rs13266634, *HHEX-*rs5015480, *CDKAL1-*rs10946398, *CDKN2A/B-*rs10811661, *IGF2BP2-*rs4402960, *FTO*-rs8050136, *TCF2-*rs7501939, *KCNQ1*-rs2237892, and *WFS1-*rs6446482. Genotyping of these SNPs was performed with an ABI SNaPshot^®^Multiplex System (Applied Biosystems, Foster City, CA, USA) in the Chinese National Human Genome Center in Shanghai. Genotyping accuracy, as determined from the genotype concordance between duplicate samples (130 samples), was 100%. The genotyping success rate was \>95% for the patient and control groups.

Statistical analysis
--------------------

Data are given as the means ± SD for quantitative variables with a normal distribution, and as medians (interquartile range) for non-normally distributed data. Fasting serum insulin, HOMA-IR, and HOMA-ί were natural logarithm-transformed to normal distributions before statistical analysis.

Characteristics were compared and tested for significant differences between patients and controls using Student\'s t test for continuous variables, and using χ^2^test for categorical variable. Chi-squared tests were used to determine whether or not individual polymorphisms were in Hardy-Weinberg equilibrium (p \> 0.05). The differences in allele and genotype frequencies between the patients with T2D and controls were analyzed using Pearson\'s χ^2^test. Logistic regression analysis was performed to calculate risk allele-specific odds ratios (ORs), 95% confidential intervals (CIs), and corresponding p -values after adjustment for gender, age, and BMI as covariates; under an additive model, 10,000 permutations were used to obtain a true estimate for statistical significance.

Linear regression was applied to test quantitative variables for differences between the genotype groups. SNPs that showed nominal evidence for an association between the age of diagnosis (AOD) for T2D, fasting plasma glucose, fasting serum insulin, HOMA-ί, and HOMA-IR were adjusted by age, gender and BMI. Additionally, BMI was adjusted for age and gender. All analyses were adjusted using linear regression on *a priori*genotypic models (dominant, additive. and recessive). Due to a lack of validity of the large sample χ2 test statistic, only the dominant model was considered for SNPs with ≤10 individuals homozygous for the minor allele (for *WFS1*and *FTO*loci in the present study).

All statistical tests were performed by PLINK, version 1.06 <http://pngu.mgh.harvard.edu/~purcell/plink> or SPSS, version 11.5 for Windows (SPSS, Inc., Chicago, IL, USA). A p-value \< 0.05 was considered statistically significant (two-tailed).

Power calculations were performed using Quanto software (available at <http://hydra.usc.edu/gxe/>), and the powers shown in Additional file [1](#S1){ref-type="supplementary-material"}, Table S1 were calculated using ORs from published studies, sample sizes and minor allele frequencies (MAF) in the present study, the prevalence of T2D in Chinese of mainland China \[[@B20]\], and the type 1 error rate (0.05).

Pairwise linkage disequilibrium (LD) coefficients (r^2^) between SNPs were calculated by Haploview software, version 4.0 (Daly Lab at the Broad Institute, Cambridge, MA, USA).

To identify studies eligible for meta-analysis, MEDLINE citations (January 2000-January 2010) were surveyed using the National Library of Medicine\'s PubMed on-line search engine with each susceptibility gene name (*CDKAL1, IGF2BP2, SLC30A8, CDKN2A/B, HHEX, KCNQ1, FTO, TCF2*, and *WFS1*) and Chinese as key words. The retrieved references were read to identify studies that examined the allelic associations between the SNPs within the above nine genetic regions and T2D in Chinese Han living in China. For meta-analysis of *WFS1*, *FTO*, and *TCF2*, the C allele of *WFS1-*rs6446482, the A allele of *FTO-*rs8050136, and the T allele of *TCF2-*rs7501939 were used as surrogates for the minor A allele of *WFS1-*rs10010131, the A allele of *FTO-*rs9939609, and the G allele of *TCF2-*rs4430796 because they are in strong LD (r^2^= 1) in a HapMap Chinese Han population. In the meta-analysis, Cochran\'s x^2^-based Q-statistic test was performed to assess heterogeneity in all of the studies included, and a random-effect model was adopted when heterogeneity existed, otherwise a fixed-effects model was appropriate. Combined ORs were calculated using the Mantel-Haenszel (fixed-effects) and DerSimonian and Laird (random-effects) tests. The significant P value of overall ORs was determined using the Z-test. All calculations for the meta-analysis were performed on Revman42 (provided by Cochrane-Collaboration, available at <http://ims.cochrane.org/revman/download/revman-4>).

Results
=======

Association study
-----------------

We have successfully genotyped all nine SNPs. There were no significant departures from the Hardy-Weinberg equilibrium for all SNPs in the control group (p \> 0.05) as assessed by a χ^2^test. In Table [2](#T2){ref-type="table"}, we present for each SNP the genotype and allele distributions, risk allele-specific ORs, and p-values under an additive genetic model after correction for gender, age, and BMI. The allele frequencies of all SNPs in our studied population (Additional file [1](#S1){ref-type="supplementary-material"}, Table S1) are comparable to those of the Chinese Han population and different from Europeans in HapMap (<http://www.hapmap.org/>, accessed Feb 2009). The associations of 7 SNPs with T2D were observed, which included, as follows: *CDKAL1-*rs10946398 (OR, 1.27; 95% CI, 1.11-1.45; empirical p = 0.0008); *IGF2BP2-*rs4402960 (OR, 1.26; 95% CI, 1.08-1.47; empirical p = 0.003); *SLC30A8-*rs13266634(OR, 1.19; 95% CI,1.04-1.37; empirical p = 0.009); *CDKN2A/B-*rs10811661(OR, 1.22; 95% CI, 1.06-1.41; empirical p = 0.005); *HHEX-*rs5015480 (OR,1.20; 95% CI, 1.01-1.42; empirical p = 0.03); and *KCNQ1-*2237892 (OR, 1.37; 95% CI, 1.19-1.69; empirical p = 1.0 × 10^-4^). Interestingly, *FTO-*rs8050136 was also associated with T2D (OR, 1.25; 95% CI, 1.02-1.52; empirical p = 0.029), which remained significant after adjustment for age, gender, and BMI (OR,1.24; 95% CI, 1.01-1.52; empirical p = 0.046). However, no association with diabetes was found for *TCF2-*rs7501939 and *WFS1*-rs6446482.

###### 

Association with type 2 diabetes in the Chinese Han population.

  Chr   SNPs         Genes        **Genotypes distribution**^**a**^   **Genotypic P**~**nominal**~   Minor/Major Alleles   RAF       Odd ratio (95%CI)   **Allelic P**~**nominal**~^**c**^   **Allelic P**~**permuted**~^**d**^                   
  ----- ------------ ------------ ----------------------------------- ------------------------------ --------------------- --------- ------------------- ----------------------------------- ------------------------------------ --------------- --------------
  9     rs10811661   *CDKN2A/B*   145:514:343                         191:514:279                    0.002                 C/**T**   0.60                0.55                                1.22(1.06-1.41)                      0.005           0.005
  8     rs13266634   *SLC30A8*    149:457:386                         179:487:327                    0.01                  T/**C**   0.62                0.57                                1.19(1.04-1.37)                      0.009           0.009
  4     rs6446482    *WFS1*       0:71:914                            2:91:880                       0.06                  C/**G**   0.96                0.95                                1.39(0.98-1.92)                      0.06            0.06
  10    rs5015480    *HHEX*       43:336:627                          31:290:668                     0.04                  **C**/T   0.21                0.18                                1.20(1.01-1.42)                      0.03            0.03
  17    rs7501939    *TCF2*       89:443:460                          73:378:490                     0.04                  **T**/C   0.31                0.28                                1.12(0.97-1.30)                      0.12            0.12
  6     rs10946398   *CDKAL1*     240:472:286                         170:498:323                    0.0006                **C**/A   0.48                0.42                                1.27(1.11-1.45)                      0.0006          0.0008
  16    rs8050136    *FTO*        17:229:761                          10:195:790                     0.08                  **A**/C   0.13                0.11                                1.24(1.01-1.52)                      0.041           0.046
  3     rs4402960    *IGF2BP2*    76:418:503                          53:356:571                     0.001                 **T**/G   0.29                0.24                                1.26(1.08-1.47)                      0.003           0.003
  11    rs2237892    *KCNQ1*      69:396:525                          107:437:415                    1.23 × 10^-5^         T**/C**   0.73                0.66                                1.37(1.19-1.69)                      2.47 × 10^-5^   1.0 × 10^-4^

a\. Genotype distributions are shown as the counts of three genotypes (bb, Bb, and BB). b, Minor allele; B, Major allele. RAF, Risk allele; OR, Risk allele-specific odds ratios calculated by logistic regression analysis. c. Adjusted for age, gender, and BMI. d. Permutation for 10,000 times. Bold indicates the risk allele.

Meta-analysis
-------------

All published studies and references are shown in Additional file [1](#S1){ref-type="supplementary-material"}, Table S2, which indicates the inconsistency for associations between *HHEX, IGF2BP2, TCF2*, and *FTO*with T2D, the low MAF of *WFS1-*rs6446482 and *FTO-*rs8050136, and the small sample sizes in all studies in Chinese compared with those in Caucasian populations. Except for the Li study \[[@B13]\] due to the lack of allelic frequencies, the data from other studies and the current study were included in this meta-analysis to improve the power in evaluating the collective evidence on the relationships of these nine genetic loci to T2D, especially *HHEX, IGF2BP2, TCF2 FTO*, and *WFS1*genetic loci. Table [3](#T3){ref-type="table"} shows the outcome of the meta-analysis. Overall, the pooled ORs for T2D were significant for *HHEX-*rs5015480 (pooled OR,1.24; *p*\< 0.00001), *IGF2BP2-*rs4402960 (pooled OR, 1.14; *p*= 0.0002), *TCF2-*rs7501939 (pooled OR, 1.16; *p*\< 0.00001), *FTO-*rs8050136 (pooled OR, 1.17; *p*\< 0.00001), *WFS1-*rs6446482 (pooled OR, 1.26; *p*= 0.009), *CDKAL1-*rs10946398 (pooled OR, 1.24; *p*\< 0.00001), *SLC30A8-*rs13266634 (pooled OR, 1.19; *p*\< 0.00001), *CDKN2A/B-*rs10811661 (pooled OR, 1.28; *p*\< 0.00001), and *KCNQ1-*2237892 (pooled OR, 1.33; *p*\< 0.00001).

###### 

Meta-analysis for SNPs at nine genetic loci in the Chinese Han population living in China.

  Chr   SNP          Gene         Risk allele   Case risk AF   Control risk AF   *P*for heterogeneity   OR (95%CI)        *P*for overall effect   References
  ----- ------------ ------------ ------------- -------------- ----------------- ---------------------- ----------------- ----------------------- ---------------------------------
  9     rs10811661   *CDKN2A/B*   T             0.60           0.54              0.07                   1.28(1.21-1.36)   \<0.00001               \[[@B10]-[@B12]\]
  8     rs13266634   *SLC30A8*    C             0.58           0.52              0.10                   1.19(1.13-1.25)   \<0.00001               \[[@B6],[@B10]-[@B12],[@B27]\]
  6     rs10946398   *CDKAL1*     C             0.45           0.41              0.03                   1.24(1.13-1.37)   \<0.00001               \[[@B10],[@B12],[@B15]\]
  11    rs 2237892   *KCNQ1*      C             0.72           0.66              0.01                   1.33(1.18-1.49)   \<0.00001               \[[@B23]-[@B26]\]
  4     rs6446482    *WFS1*       G             0.96           0.95              0.53                   1.26(1.06-1.51)   0.009                   \[[@B12]\]
  10    rs5015480    *HHEX*       C             0.20           0.16              0.12                   1.24(1.12-1.38)   \<0.00001               \[[@B10],[@B11]\]
  17    rs7501939    *TCF2*       T             0.28           0.26              0.88                   1.16(1.08-1.24)   \<0.00001               \[[@B5],[@B38]\]
  3     rs4402960    *IGF2BP2*    T             0.27           0.24              0.22                   1.14(1.06-1.22)   0.0002                  \[[@B10],[@B11],[@B15]\]
  16    rs8050136    *FTO*        A             0.14           0.12              0.80                   1.17(1.09-1.27)   \<0.00001               \[[@B11],[@B12],[@B14],[@B30]\]

AF: allele frequency; OR: Odds ratio; CI: confidence interval; All of the calculations for the meta-analysis were carried out on Revman4.2. Cochran\'s x^2^-based Q-statistic test was used to assess heterogeneity in all studies, and a random-effect model was adopted when heterogeneity existed, otherwise a fixed-effects model was appropriate. Combined ORs were calculated using the Mantel-Haenszel (fixed-effects) and DerSimonian and Laird (random-effects) tests. The significant P value of the overall ORs was determined using a Z-test.

Genotype-phenotype relationship analysis
----------------------------------------

*Genotype-age of diagnosis (AOD) for diabetes*For the patients with T2D, multiple linear regression was used to evaluate the effect of nine representative SNPs on AOD with adjustment for gender and BMI under *a priori*models. The analysis revealed that only *WFS1-*rs6446482 was negatively related to AOD under a dominant model (p = 0.02), and the patients with one or two risk alleles of *WFS1-*rs6446482 were diagnosed approximately 3 years earlier than those without risk alleles (49 ± 11 years versus 52 ± 11 years, p = 0.03). Prompted by this observation, we performed a subgroup analysis of 406 early-onset T2D patients (age of diagnosis ≦45 years) and 973 control subjects, showing that *WFS1-*rs6446482 was significantly associated with early-onset T2D (risk allele-specific OR, 1.96; 95% CI, 1.05-4.76; nominal p = 0.03; empiric p = 0.03) after adjustment for gender, age, and BMI.

*Genotype-BMI*For analysis of the genotype-BMI relationship, only the control subjects were examined because the treatment for T2D might distort the relationship. Only *FTO-*rs8050136 of nine genetic loci was found to be significantly associated with BMI (p = 0.04) after adjusting for gender and age as covariates. The individuals with one or two risk alleles had a higher BMI (25. ± 3.3 kg/m^2^, n = 205) than those without a risk allele (24.8 ± 3.4 kg/m^2^, n = 790; p = 0.04).

*Genotype-beta cell function and insulin resistance*Because the insulin level might be influenced by a hyperglycemic agent, 493 non-diabetic control subjects with fasting insulin concentrations available were studied. Only at the FTO and CDKAL1 loci was a relationship between SNP and phenotype observed. As shown in Table [4](#T4){ref-type="table"}, the individuals with a risk allele of *FTO-*rs8050136 had a higher HOMA-ί, HOMA-IR, BMI, and fasting serum insulin level than those without the risk allele(under a dominant model), and the effects of *FTO*on HOMA-ί, HOMA-IR, and the fasting serum insulin level were independent of gender, age, and BMI. In addition, *CDKAL1-*rs10946398 significantly affected beta cell function independent of gender, age, and BMI, and the individuals with 2 risk alleles had a lower HOMA-ί than those without a risk allele (under the recessive model).

###### 

The genotype-phenotype relationship in control individuals at CDKAL1 and FTO genetic loci.

  SNPs                 Genotype            Male/Female   Age (yrs)   **BMI (kg/m**^**2**^**)**   Fasting glucose (mmol/l)   Fasting insulin (pmol/l)   HOMA-ί              HOMA-IR
  -------------------- ------------------- ------------- ----------- --------------------------- -------------------------- -------------------------- ------------------- -------------------
  *CDKAL1*rs10946398   AA                  40/117        57 ± 8      25.1 ± 2.9                  5.2 ± 0.4                  50.1(34.1-71.7)            81.5(59.2-118.1)    1.6(1.2-2.5)
                       AC                  65/188        57 ± 8      25.1 ± 3.2                  5.3 ± 0.4                  46.7(36.9-66.9)            80.5(57.3-109.8)    1.5(1.1-2.3)
                       CC                  22/56         57 ± 9      25.9 ± 3.6                  5.4 ± 0.4                  48.1(36.9-64.8)            77.1(57.4-106.3)    1.6(1.2-2.3)
                       Dominant p-value    \-            \-          0.650                       0.140                      0.268                      0.142               0.268
                       Additive p-value    \-            \-          0.131                       0.161                      0.525                      **0.034(0.019)a**   0.155
                       Recessive p-value   \-            \-          0.053                       **0.044(0.046)a**          0.802                      **0.043(0.021)a**   0.228
  *FTO*rs8050136       CC                  108/278       57 ± 8      25.1 ± 3.2                  5.3 ± 0.4                  45.3(32.7-63.4)            76.6(54.3-106.3)    1.5(1.1-2.2)
                       CA/AA               19/85         57 ± 8      25.8 ± 3.2                  5.2 ± 0.4                  55.7(43.2-75.2)            94.3(73.5-129.6)    1.8(1.4-2.6)
                       Dominant p value    \-            \-          **0.04(0.037)b**            0.148                      **\<0.00001(0.005)a**      **0.004(0.017)a**   **0.005(0.035)a**

Data are the means ± SD, or median(interquartile range). Test models refer to the minor allele. Only the dominant model was considered in which the minor allele homozygote count was ≤10. Bold: P-value \< 0.05. Unadjusted p values without parentheses and p values with parentheses adjusted for a (gender, age, and BMI) and b (gender and age).

Discussion
==========

In the present study, we have replicated the associations between seven SNPs (*CDKAL1-*rs10946398, *IGF2BP2-*rs4402960, *SLC30A8-*rs13266634, *CDKN2A/B-*rs10811661, *HHEX-*rs5015480, *FTO-*rs8050136, and *KCNQ1-*rs2237892) with T2D in the Chinese Han population living in China, and an association between *WFS1-*rs6446482 with early-onset T2D was also identified in the subgroup analysis. For the genotype-phenotype analysis in control subjects, we found that the SNP at *FTO*loci showed a significant association with BMI, beta cell function, and insulin sensitivity. Moreover, we observed the influence of *CDKAL1*on beta cell function, and our meta-analysis also indicated the SNPs at *TCF2-*rs7501939 and *WFS1-*rs6446482 were associated with T2D.

*SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2*, and *FTO*are among the first cohort of susceptibility genes discovered in relatively small samples by GWAS with ORs ranging from 1.14-1.20 \[[@B1]-[@B6]\]. In the present study, the OR values for the risk alleles range from 1.19-1.27, which are slightly higher than the Caucasian population \[[@B1]-[@B6]\], and slightly different from other Chinese studies. This is partly due to the features of our study (e.g., small sample sizes, enriched subjects with earlier onset T2D, and older subjects without a family history of T2D in the control group) or the difference in the studied population in genetic background as observed for the *TCF7L2*and *KCNQ1*genes in previous reports \[[@B7],[@B21],[@B22]\]. Based on our observation, we found that the minor allele frequencies of *FTO, WFS1, TCF2*, *HHEX*, and *IGF2BP2*were much lower, while those of *CDKAL1, CDKN2A/B*, *SLC30A8*, and *KCNQ1*were much higher than in the Caucasian population (Additional file [1](#S1){ref-type="supplementary-material"}, Table S1), indicating the different genetic background between Caucasians and the Chinese population. Our findings on *CDKAL1*, *SLC30A8*, *CDKN2A/B*, and *KCNQ1*are further supported by several recent studies in the Chinese population \[[@B10]-[@B12],[@B23]-[@B27]\]. However, for *IGF2BP2*, no significant association was demonstrated with T2D \[[@B10],[@B11]\]. For *HHEX*, a relationship between the SNPs at the *HHEX*locus and T2D was reported among Chinese living in Shanghai, but not among Chinese in Beijing, even in the same study \[[@B10]\]. We believe that the inconsistent results of these studies are due, at least in part, to the small sample size \[[@B10]\] and the different enrollment criteria. For example, the plasma glucose at 2 hours during the OGTT was not determined and some subjects with impaired glucose tolerance(IGT) or T2D might have been falsely classified into the control group \[[@B10]\], or some adolescents in the control group may develop T2D in the future \[[@B11]\]. Therefore, the meta-analysis of the combined data from these published studies and our study is necessary for evaluating the association of these genetic loci with T2D and the effect of size in the Chinese population.

The studies in other ethnic groups have made clear that the association between *FTO*and T2D is mediated through its effect on body weight \[[@B2],[@B3],[@B28],[@B29]\]. In the present study, we have confirmed the association between *FTO*and BMI and T2D, and the association with T2D remained of borderline significance (p = 0.046), even after adjustment for BMI. The independent effect of *FTO*on T2D is consistent with a recent study \[[@B14]\]. It is worth noticing that the study results on *FTO*in a Chinese population have been conflicting. The study in Chinese living in Taiwan has reported this association with BMI, but not T2D \[[@B30]\]. However, another study in a Chinese population living in Shanghai did not show an association between *FTO*-rs8050136 and BMI or T2D \[[@B13]\]. The discrepancy is partly due to population-specific bias, insufficient power, and the effects of duration and treatment for T2D, which may have distorted the real relationships among BMI, genotypes, and T2D. Europeans and Asians are different in their environmental risk profiles, body composition, and genetic background. In particular, Asians are at risk for T2D at a lower level of obesity, partly due to their increased predisposition to visceral adiposity \[[@B31]\] and reduced pancreatic β-cell function \[[@B32]\]. Our pooled analysis demonstrated *FTO*really contributed to T2D in Chinese. Unfortunately, the individual BMI from all published studies are not available for meta-analysis and so it is difficult to determine whether or not the association is really independent of BMI. As observed in the present study, *FTO-*rs8050136 may directly or indirectly affect HOMA-ί and HOMA-IR, and a reasonable interpretation is that the control subjects who carry the risk allele of *FTO*are prone to insulin resistance, and are able to increase insulin secretion to completely compensate for low insulin sensitivity to keep glucose homeostasis. Thus, it is necessary to clarify the pathogenesis of the contribution of *FTO*to T2D.

It has been shown that common SNPs at the WFS1 locus are clearly associated with T2D in a Caucasian population \[[@B8],[@B33]\], but not in a Chinese population in a recent study with insufficient power \[[@B12]\]. However, we observed an association between *WFS1*-rs6446482 with T2D in our meta-analysis, and early-onset T2D in our own sample. Wolfram syndrome, characterized by early-onset diabetes, optic atrophy, deafness, and diabetes insipidus is due to mutations of the WFS1 gene \[[@B34]\], which regulates ί cell function in mice \[[@B35]\] and glucagon-like peptide 1-induced insulin secretion in humans \[[@B36]\], suggesting that impaired beta cell function in subjects with the risk allele of WFS1 may promote the onset of T2D as seen in other monogenetic diabetes \[[@B37],[@B38]\]. Thus, it is necessary to replicate this study in a larger sample and sequence this gene for real causative variants.

The C allele of rs7501939 and the A allele of rs4430796 in the *TCF2*gene were shown by GWAS to confer risk for prostate cancer and are protective for T2D \[[@B5]\]. However, that study did not show a significant association between *TCF2-*rs7501939 with T2D in a Chinese sample \[[@B5]\], consistent with the results of our study. The negative finding should be attributed to the insufficient power of this study (Additional file [1](#S1){ref-type="supplementary-material"}, Table S1). Nevertheless, in another Chinese study involving *TCF2-*rs4430796 \[[@B38]\], the association was replicated. A meta-analysis of combined data from both the previous study \[[@B38]\] and our study in Chinese confirmed the findings.

There are now as many as 17 genetic loci associated with T2D. In our previous Chinese Han studies \[[@B22],[@B39],[@B40]\], we have assessed the effects of *PPARG, KCNJ11*, and *TCF7L2*, and successfully replicated the associations between the *KCNJ11*and *TCF7L2*loci with T2D. However, the remaining six genetic loci were identified by meta-analysis of GWAS, including *JAZF1, TSPAN8-LGR5, THADA, ADAMTS9, NOTCH2-ADAM30, and MTNR1B*, of which only *MTNR1B*in one study was shown to increase the risk for T2D and an increased fasting plasma glucose concentration in the Chinese Han \[[@B12],[@B41]\]. Therefore, further investigation with a large sample and meta-analysis is needed to confirm the roles in the Chinese Han population.

Conclusions
===========

In summary, the present study has confirmed an association between genetic variations at *CDKAL1, IGF2BP2, SLC30A8, CDKN2A/B, HHEX, KCNQ1*, and *FTO*loci with T2D in the Chinese Han population living in China. Our meta-analysis has provided the evidence that the variants at *TCF2*and *WFS1*genetic loci also contribute to the genetic susceptibility for T2D in Chinese.
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